Market Research

Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer Type (Invasive lobular breast cancer, Ductal carcinoma in situ (DCIS), Triple-negative breast cancer, Inflammatory breast cancer, Others), By Test Type (Clinical Breast Exam,

Best Price Guarantee Publisher Published Date SKU
from $3,500 Straits Research November, 2024 STRA19656709
Best Price Guarantee
Price from $3,500
Publisher Straits Research
Published Date November, 2024
SKU STRA19656709

Breast Cancer Diagnostics Market Analysis and Insights

The Breast Cancer Diagnostics Market size is anticipated to reach USD 4.96 billion in 2024 and it is projected to reach USD 9.65 billion by 2033, growing at a CAGR of 7.62% during the forecast period.

The Global Breast Cancer Diagnostics Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Breast Cancer Diagnostics Market growth, Size report provides a comprehensive analysis of the Healthcare IT industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry Experts, Breast Cancer Diagnostics Market includes major supplies & Independent Consultants among others.

Global Market Scope and Breast Cancer Diagnostics Market

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Breast Cancer Diagnostics Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Breast Cancer Diagnostics Market Country Level Analysis

The Global Breast Cancer Diagnostics Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Breast Cancer Diagnostics Market share and status of critical industries is included in the report, covering. Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

Top Players in Breast Cancer Diagnostics Market

Some of the other major highlights of the demand for Breast Cancer Diagnostics Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter’s Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Breast Cancer Diagnostics Market during the forecast period.

  • Siemens Healthineers AG
  • Kheiron Medical Technologies
  • Bio-Rad Laboratories
  • Hologic, Inc.
  • Koninklijke Philips N.V.
  • Quest Diagnostics Incorporated
  • FUJIFILM Holdings Corporation
  • GE Healthcare
  • Illumina, Inc.
  • Metaltronica SpA
  • Carestream Health

Market Segmentation

The Global Breast Cancer Diagnostics Market Share, Demand provides the most up-to-date Healthcare IT industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.
  • By Cancer Type
    • Invasive lobular breast cancer
    • Ductal carcinoma in situ (DCIS)
    • Triple-negative breast cancer
    • Inflammatory breast cancer
    • Others
  • By Test Type
    • Clinical Breast Exam
    • Blood Tests
    • Imaging Tests
      • Mammogram
      • MRI
      • Ultrasound
      • PET
      • Others
    • Biopsies
      • Excisional biopsy
      • Incisional biopsy
      • Core biopsy
      • Fine-needle aspiration (FNA) biopsy
      • Others
    • Others
  • By Stage
    • Stage I
    • Stage II
    • Stage III
    • Stage IV
  • By End-User
    • Hospitals and Clinics
    • Cancer Diagnostic Centers
    • Cancer Research Institutes
    • Ambulatory Surgical Centers
    • Others

Regions Coverd
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Russia
    • Nordic
    • Benelux
    • Rest of Europe
  • APAC
    • China
    • Korea
    • Japan
    • India
    • Australia
    • Singapore
    • Taiwan
    • South East Asia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • UAE
    • Turkey
    • Saudi Arabia
    • South Africa
    • Egypt
    • Nigeria
    • Rest of MEA
  • LATAM
    • Brazil
    • Mexico
    • Argentina
    • Chile
    • Colombia
    • Rest of LATAM

Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market’s development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.


1 Executive Summary
2 Research Scope & Segmentation
2.1 Research Objectives
2.2 Limitations & Assumptions
2.3 Market Scope & Segmentation
2.4 Currency & Pricing Considered
3 Market Opportunity Assessment
3.1 Emerging Regions / Countries
3.2 Emerging Companies
3.3 Emerging Applications / End Use
4 Market Trends
4.1 Drivers
4.2 Market Warning Factors
4.3 Latest Macro Economic Indicators
4.4 Geopolitical Impact
4.5 Technology Factors
5 Market Assessment
5.1 Porters Five Forces Analysis
5.2 Value Chain Analysis
6 Global Breast Cancer Diagnostics Market Size Analysis
6.1 By Cancer Type
6.1.1 Invasive lobular breast cancer
6.1.2 Ductal carcinoma in situ (DCIS)
6.1.3 Triple-negative breast cancer
6.1.4 Inflammatory breast cancer
6.1.5 Others
6.2 By Test Type
6.2.1 Clinical Breast Exam
6.2.2 Blood Tests
6.2.3 Imaging Tests
6.2.3.1 Mammogram
6.2.3.2 MRI
6.2.3.3 Ultrasound
6.2.3.4 PET
6.2.3.5 Others
6.2.4 Biopsies
6.2.4.1 Excisional biopsy
6.2.4.2 Incisional biopsy
6.2.4.3 Core biopsy
6.2.4.4 Fine-needle aspiration (FNA) biopsy
6.2.4.5 Others
6.2.5 Others
6.3 By Stage
6.3.1 Stage I
6.3.2 Stage II
6.3.3 Stage III
6.3.4 Stage IV
6.4 By End-User
6.4.1 Hospitals and Clinics
6.4.2 Cancer Diagnostic Centers
6.4.3 Cancer Research Institutes
6.4.4 Ambulatory Surgical Centers
6.4.5 Others
7 North America Market Analysis
7.1 By Cancer Type
7.1.1 Invasive lobular breast cancer
7.1.2 Ductal carcinoma in situ (DCIS)
7.1.3 Triple-negative breast cancer
7.1.4 Inflammatory breast cancer
7.1.5 Others
7.2 By Test Type
7.2.1 Clinical Breast Exam
7.2.2 Blood Tests
7.2.3 Imaging Tests
7.2.3.1 Mammogram
7.2.3.2 MRI
7.2.3.3 Ultrasound
7.2.3.4 PET
7.2.3.5 Others
7.2.4 Biopsies
7.2.4.1 Excisional biopsy
7.2.4.2 Incisional biopsy
7.2.4.3 Core biopsy
7.2.4.4 Fine-needle aspiration (FNA) biopsy
7.2.4.5 Others
7.2.5 Others
7.3 By Stage
7.3.1 Stage I
7.3.2 Stage II
7.3.3 Stage III
7.3.4 Stage IV
7.4 By End-User
7.4.1 Hospitals and Clinics
7.4.2 Cancer Diagnostic Centers
7.4.3 Cancer Research Institutes
7.4.4 Ambulatory Surgical Centers
7.4.5 Others
7.4 U.S.
7.5 Canada
8 Europe Market Analysis
8.1 By Cancer Type
8.1.1 Invasive lobular breast cancer
8.1.2 Ductal carcinoma in situ (DCIS)
8.1.3 Triple-negative breast cancer
8.1.4 Inflammatory breast cancer
8.1.5 Others
8.2 By Test Type
8.2.1 Clinical Breast Exam
8.2.2 Blood Tests
8.2.3 Imaging Tests
8.2.3.1 Mammogram
8.2.3.2 MRI
8.2.3.3 Ultrasound
8.2.3.4 PET
8.2.3.5 Others
8.2.4 Biopsies
8.2.4.1 Excisional biopsy
8.2.4.2 Incisional biopsy
8.2.4.3 Core biopsy
8.2.4.4 Fine-needle aspiration (FNA) biopsy
8.2.4.5 Others
8.2.5 Others
8.3 By Stage
8.3.1 Stage I
8.3.2 Stage II
8.3.3 Stage III
8.3.4 Stage IV
8.4 By End-User
8.4.1 Hospitals and Clinics
8.4.2 Cancer Diagnostic Centers
8.4.3 Cancer Research Institutes
8.4.4 Ambulatory Surgical Centers
8.4.5 Others
8.4 U.K.
8.5 Germany
8.6 France
8.7 Spain
8.8 Italy
8.9 Russia
8.10 Nordic
8.11 Benelux
8.12 Rest of Europe
9 APAC Market Analysis
9.1 By Cancer Type
9.1.1 Invasive lobular breast cancer
9.1.2 Ductal carcinoma in situ (DCIS)
9.1.3 Triple-negative breast cancer
9.1.4 Inflammatory breast cancer
9.1.5 Others
9.2 By Test Type
9.2.1 Clinical Breast Exam
9.2.2 Blood Tests
9.2.3 Imaging Tests
9.2.3.1 Mammogram
9.2.3.2 MRI
9.2.3.3 Ultrasound
9.2.3.4 PET
9.2.3.5 Others
9.2.4 Biopsies
9.2.4.1 Excisional biopsy
9.2.4.2 Incisional biopsy
9.2.4.3 Core biopsy
9.2.4.4 Fine-needle aspiration (FNA) biopsy
9.2.4.5 Others
9.2.5 Others
9.3 By Stage
9.3.1 Stage I
9.3.2 Stage II
9.3.3 Stage III
9.3.4 Stage IV
9.4 By End-User
9.4.1 Hospitals and Clinics
9.4.2 Cancer Diagnostic Centers
9.4.3 Cancer Research Institutes
9.4.4 Ambulatory Surgical Centers
9.4.5 Others
9.4 China
9.5 Korea
9.6 Japan
9.7 India
9.8 Australia
9.9 Singapore
9.10 Taiwan
9.11 South East Asia
9.12 Rest of Asia-Pacific
10 Middle East and Africa Market Analysis
10.1 By Cancer Type
10.1.1 Invasive lobular breast cancer
10.1.2 Ductal carcinoma in situ (DCIS)
10.1.3 Triple-negative breast cancer
10.1.4 Inflammatory breast cancer
10.1.5 Others
10.2 By Test Type
10.2.1 Clinical Breast Exam
10.2.2 Blood Tests
10.2.3 Imaging Tests
10.2.3.1 Mammogram
10.2.3.2 MRI
10.2.3.3 Ultrasound
10.2.3.4 PET
10.2.3.5 Others
10.2.4 Biopsies
10.2.4.1 Excisional biopsy
10.2.4.2 Incisional biopsy
10.2.4.3 Core biopsy
10.2.4.4 Fine-needle aspiration (FNA) biopsy
10.2.4.5 Others
10.2.5 Others
10.3 By Stage
10.3.1 Stage I
10.3.2 Stage II
10.3.3 Stage III
10.3.4 Stage IV
10.4 By End-User
10.4.1 Hospitals and Clinics
10.4.2 Cancer Diagnostic Centers
10.4.3 Cancer Research Institutes
10.4.4 Ambulatory Surgical Centers
10.4.5 Others
10.4 UAE
10.5 Turkey
10.6 Saudi Arabia
10.7 South Africa
10.8 Egypt
10.9 Nigeria
10.10 Rest of MEA
11 LATAM Market Analysis
11.1 By Cancer Type
11.1.1 Invasive lobular breast cancer
11.1.2 Ductal carcinoma in situ (DCIS)
11.1.3 Triple-negative breast cancer
11.1.4 Inflammatory breast cancer
11.1.5 Others
11.2 By Test Type
11.2.1 Clinical Breast Exam
11.2.2 Blood Tests
11.2.3 Imaging Tests
11.2.3.1 Mammogram
11.2.3.2 MRI
11.2.3.3 Ultrasound
11.2.3.4 PET
11.2.3.5 Others
11.2.4 Biopsies
11.2.4.1 Excisional biopsy
11.2.4.2 Incisional biopsy
11.2.4.3 Core biopsy
11.2.4.4 Fine-needle aspiration (FNA) biopsy
11.2.4.5 Others
11.2.5 Others
11.3 By Stage
11.3.1 Stage I
11.3.2 Stage II
11.3.3 Stage III
11.3.4 Stage IV
11.4 By End-User
11.4.1 Hospitals and Clinics
11.4.2 Cancer Diagnostic Centers
11.4.3 Cancer Research Institutes
11.4.4 Ambulatory Surgical Centers
11.4.5 Others
11.4 Brazil
11.5 Mexico
11.6 Argentina
11.7 Chile
11.8 Colombia
11.9 Rest of LATAM
12 Competitive Landscape
12.1 Global Breast Cancer Diagnostics Market Share By Players
12.2 M & A Agreements & Collaboration Analysis
13 Market Players Assessment
13.1 American International Industries (GIGI)
13.1.1 Overview
13.1.2 Business Information
13.1.3 Revenue
13.1.4 ASP
13.1.5 Swot Analysis
13.1.6 Recent Developments
13.2 Kheiron Medical Technologies
13.3 Bio-Rad Laboratories
13.4 Hologic, Inc.
13.5 Koninklijke Philips N.V.
13.6 Quest Diagnostics Incorporated
13.7 FUJIFILM Holdings Corporation
13.8 GE Healthcare
13.9 Illumina, Inc.
13.10 Metaltronica SpA
13.11 Carestream Health
14 Research Methodology
14.1 Research Data
14.1.1 Secondary Data
14.1.1.1 Major secondary sources
14.1.1.2 Key data from secondary sources
14.1.2 Primary Data
14.1.2.1 Key data from primary sources
14.1.2.2 Breakdown of primaries
14.1.3 Secondary And Primary Research
14.1.3.1 Key industry insights
14.2 Market Size Estimation
14.2.1 Bottom-Up Approach
14.2.2 Top-Down Approach
14.2.3 Market Projection
14.3 Research Assumptions
14.3.1 Assumptions
14.4 Limitations
14.5 Risk Assessment
15 Appendix
15.1 Discussion Guide
15.2 Customization Options
15.3 Related Reports
16 Disclaimer

$3,500
$4,500

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings